{"schema_version":"secwatch.filing_event.v1","accession":"0001091818-21-000150","form_type":"8-K","ticker":"BFNH","cik":"0001310488","company_name":"BIOFORCE NANOSCIENCES HOLDINGS, INC.","filed_at":"2021-11-30T23:59:59+00:00","discovered_at":"2026-05-14T18:04:11.982116+00:00","generated_at":"2026-06-28T04:47:39.323710+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"BioForce Nanosciences appoints Co-CEOs and President, CEO Merle Ferguson resigns","bullets":["CEO & President Merle Ferguson resigned Nov 30, 2021; remains Chairman, no dispute with company.","Steve Gagnon and John LaViolette appointed Co-CEOs effective Nov 30, 2021.","Sasha Shapiro appointed President effective Nov 30, 2021.","New officers are from Element Global (OTC Pink) and have entertainment industry backgrounds."],"urls":{"canonical":"https://secwatch.observer/filing/0001091818-21-000150","json":"https://secwatch.observer/filing/0001091818-21-000150.json","markdown":"https://secwatch.observer/filing/0001091818-21-000150.md","text":"https://secwatch.observer/filing/0001091818-21-000150.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1310488/000109181821000150/0001091818-21-000150-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1310488/000109181821000150/bfnh8k2021.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T04:47:39.323710+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0cdb1d66a6","claim":"Merle Ferguson resigned as Chief Executive Officer and President at BIOFORCE NANOSCIENCES HOLDINGS, INC..","evidence_excerpt":"the Board of Directors accepted the resignation of Mr. Merle Ferguson as Chief Executive Officer and President, effective November 30, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1310488/000109181821000150/0001091818-21-000150-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer and President"}],"fact_type":"executive_change"},{"claim_id":"1a19dde7fb","claim":"John LaViolette was appointed as Co-Chief Executive Officer at BIOFORCE NANOSCIENCES HOLDINGS, INC..","evidence_excerpt":"appointed both Mr. Steve Gagnon and Mr. John LaViolette as Co-Chief Executive Officers (Co-CEOs), effective November 30, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1310488/000109181821000150/0001091818-21-000150-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Co-Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"558a27ee3b","claim":"Sasha Shapiro was appointed as President at BIOFORCE NANOSCIENCES HOLDINGS, INC..","evidence_excerpt":"appointed Sasha Shapiro as President, effective November 30, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1310488/000109181821000150/0001091818-21-000150-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President"}],"fact_type":"executive_change"},{"claim_id":"c9166e0412","claim":"Steve Gagnon was appointed as Co-Chief Executive Officer at BIOFORCE NANOSCIENCES HOLDINGS, INC..","evidence_excerpt":"appointed both Mr. Steve Gagnon and Mr. John LaViolette as Co-Chief Executive Officers (Co-CEOs), effective November 30, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1310488/000109181821000150/0001091818-21-000150-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Co-Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}